These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1084 related items for PubMed ID: 28242135

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U, Signore PE, Walkinshaw G, Seeley TW, Brenner MC, Wang Q, Guo G, Arend MP, Flippin LA, Chow FA, Gervasi DC, Kjaergaard CH, Langsetmo I, Guenzler V, Liu DY, Klaus SJ, Lin A, Neff TB.
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
    Sanghani NS, Haase VH.
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):253-266. PubMed ID: 31477256
    [Abstract] [Full Text] [Related]

  • 6. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
    Kile M, Sudchada P.
    Int Urol Nephrol; 2021 Feb; 53(2):283-290. PubMed ID: 32770437
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
    Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KP, Neff TB.
    Clin J Am Soc Nephrol; 2016 Jun 06; 11(6):982-991. PubMed ID: 27094610
    [Abstract] [Full Text] [Related]

  • 10. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
    Chen J, Shou X, Xu Y, Jin L, Zhu C, Ye X, Mei Z, Chen P.
    Aging (Albany NY); 2023 Mar 27; 15(6):2237-2274. PubMed ID: 36988549
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
    Doggrell SA.
    Expert Opin Pharmacother; 2022 May 27; 23(7):769-773. PubMed ID: 35380500
    [Abstract] [Full Text] [Related]

  • 13. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M, Tanaka T, Nangaku M.
    Pharmacol Ther; 2022 Nov 27; 239():108272. PubMed ID: 36031160
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E, Cho KH, Harris ST, Flindt NR, Watt RK, Pai AB.
    Expert Opin Investig Drugs; 2020 Aug 27; 29(8):831-844. PubMed ID: 32476498
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Więcek A, Blackorby A, Cizman B, Cobitz AR, Davies R, Dole J, Kler L, Meadowcroft AM, Zhu X, McMurray JJV, ASCEND-D Study Group.
    N Engl J Med; 2021 Dec 16; 385(25):2325-2335. PubMed ID: 34739194
    [Abstract] [Full Text] [Related]

  • 20. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
    Zuk A, Si Z, Loi S, Bommegowda S, Hoivik D, Danthi S, Molnar G, Csizmadia V, Rabinowitz M.
    J Pharmacol Exp Ther; 2022 Oct 16; 383(1):11-24. PubMed ID: 35926869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.